Premium
Successful Renal Transplantation in Factor H Autoantibody Associated HUS with CFHR1 and 3 Deficiency and CFH Variant G2850T
Author(s) -
Waters A. M.,
Pappworth I.,
Marchbank K.,
Bockenhauer D.,
Tullus K.,
Pickering M. C.,
Strain L.,
Sebire N.,
Shroff R.,
Marks S. D.,
Goodship T. H. J.,
Rees L.
Publication year - 2010
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2009.02870.x
Subject(s) - medicine , autoantibody , atypical hemolytic uremic syndrome , immunology , rituximab , immunosuppression , transplantation , antibody , complement system
Factor H (CFH) autoantibodies are associated with atypical hemolytic uremic syndrome (aHUS). Peritransplantation plasma exchange therapy and intensification of immunosuppression, with adjuvant use of anti‐CD20 monoclonal antibodies has recently been advocated for cases of CFH‐autoantibody associated aHUS. In this report, we describe successful deceased donor renal transplantation in a case of CFH‐autoantibody associated aHUS with combined CFHR1 and 3 deficiency in addition to the CFH sequence variant, (cG2850T, pGln950His). CFH‐autoantibodies were detected 2 weeks prior to transplantation. Disease recurrence was not observed using basiliximab, an IL2‐receptor antagonist and high‐dose corticosteroids with mycophenolate mofetil. Adjuvant therapies such as Rituximab nor intensification of plasma therapy were employed. Consequently, careful consideration needs to be given to the use of additional immunosuppression in certain cases of CFH‐autoantibody associated aHUS. Serial measurement of CFH‐autoantibodies is required in the immediate pre‐ and posttransplantation period to further clarify their role as a factor in the recurrence of aHUS posttransplantation. Furthermore, delineation of the functional significance of CFH‐autoantibodies is warranted in individual cases.